Articles published by Pfizer Inc.
Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases
Today 6:45 EST
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
November 11, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 10, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Appoints Cecile Guegan as Chief Financial Officer
November 03, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
October 26, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
October 24, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
October 07, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Declares Fourth-Quarter 2026 Dividend
October 06, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
October 01, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
September 28, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 15, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 08, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
From Pfizer Inc.
Via Business Wire
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
July 30, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
July 22, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Declares Third-Quarter 2026 Dividend
June 24, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
June 24, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
June 23, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Announces Chief Financial Officer Transition
June 18, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
June 06, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 01, 2026
From Pfizer Inc.
Via Business Wire
Tickers
PFE